







 Patient Name
 : RAJESH KUMAR CHATTERJEE
 Ref Dr.
 : Dr.MEDICAL OFFICER

 Age
 : 51 Y 8 M 14 D
 Collection Date
 : 13/Jan/2024 10:15AM

Gender : M Report Date : 13/Jan/2024 06:16PM



## DEPARTMENT OF BIOCHEMISTRY

Test Name	Result	Bio Ref. Interval	Unit	
PHOSPHORUS-INORGANIC,BLOOD, GEL	3.6	2.4-5.1 mg/dL	mg/dL	
SERUM (Method:Phosphomolybdate/UV)				

\*\*\* End Of Report \*\*\*

MBBS MD (Biochemistry) Consultant Biochemist



Lab No. : DUR/13-01-2024/SR8628592 Lab Add. : CITY CENTER, DURGAPUR PIN-7132

 Patient Name
 : RAJESH KUMAR CHATTERJEE
 Ref Dr.
 : Dr.MEDICAL OFFICER

 Age
 : 51 Y 8 M 14 D
 Collection Date
 : 13/Jan/2024 10:15AM

 Gender
 : M
 Report Date
 : 13/Jan/2024 04:24PM



#### DEPARTMENT OF BIOCHEMISTRY

		OF DIOCHEMISTRY		
Test Name	Result	Bio Ref. Interval	Unit	
ALKALINE PHOSPHATASE (Method:AMP)	100	53-128 U/L	U/L	
BILIRUBIN (DIRECT) (Method:Diazotized DCA Method)	0.50	< 0.3	mg/dL	
*BILIRUBIN (TOTAL) , GEL SERUM				
BILIRUBIN (TOTAL) (Method:Diazotized DCA Method)	1.20	< 1.2	mg/dL	
SGPT/ALT (Method:IFCC Kinetic Method)	<u>49</u>	< 41	U/L	
SODIUM,BLOOD (Method:ISE DIRECT)	137	136 - 145	mEq/L	
CREATININE, BLOOD (Method:ENZYMATIC)	0.95	0.70 - 1.3 mg/dl	mg/dL	
*TOTAL PROTEIN [BLOOD] ALB:GL	O RATIO , .			
TOTAL PROTEIN (Method:BIURET METHOD)	<u>6.10</u>	6.6 - 8.7	g/dL	
ALBUMIN (Method:BCG)	4.4	3.5-5.2 g/dl	g/dl	
GLOBULIN (Method:Calculated)	<u>1.70</u>	1.8-3.2	g/dl	
AG Ratio (Method:Calculated)	<u>2.59</u>	1.0 - 2.5		
GLUCOSE,PP (Method:GOD POD)	<u>138</u>	(70 - 140 mg/dl)		

\*GLYCATED HAEMOGLOBIN (HBA1C), EDTA WHOLE BLOOD

GLYCATED HEMOGLOBIN (HBA1C) 4.7 \*\*\*FOR BIOLOGICAL REFERENCE %

INTERVAL DETAILS , PLEASE REFER TO THE BELOW MENTIONED REMARKS/NOTE WITH ADDITIONAL CLINICAL

**INFORMATION** \*\*\*

HbA1c (IFCC) 28.0 mmol/mol (Method:HPLC)

 ${\bf Clinical\ Information}\quad and\ {\bf Laboratory\ clinical\ interpretation\ on\ Biological\ Reference\ Interval:}$ 

Analyzer used: BIORAD D-10

Method: HPLC

Recommendations for glycemic targets

- Ø Patients should use self-monitoring of blood glucose (SMBG) and HbA1c levels to assess glycemic control.
- Ø The timing and frequency of SMBG should be tailored based on patients' individual treatment, needs, and goals.
- Ø Patients should undergo HbA1c testing at least twice a year if they are meeting treatment goals and have stable glycemic control.
- Ø If a patient changes treatment plans or does not meet his or her glycemic goals, HbA1c testing should be done quarterly.



Lab No. : DUR/13-01-2024/SR8628592 Lab Add. : CITY CENTER, DURGAPUR PIN-7132

 Patient Name
 : RAJESH KUMAR CHATTERJEE
 Ref Dr.
 : Dr.MEDICAL OFFICER

 Age
 : 51 Y 8 M 14 D
 Collection Date
 : 13/Jan/2024 10:15AM

 Gender
 : M
 Report Date
 : 13/Jan/2024 04:24PM



#### DEPARTMENT OF BIOCHEMISTRY

Test Name	Result	Bio Ref. Interval	Unit

Ø For most adults who are not pregnant, HbA1c levels should be <7% to help reduce microvascular complications and macrovascular disease. Action suggested >8% as it indicates poor control.

Ø Some patients may benefit from HbA1c goals that are stringent.

Result alterations in the estimation has been established in many circumstances, such as after acute/ chronic blood loss, for example, after surgery, blood transfusions, hemolytic anemia, or high erythrocyte turnover; vitamin  $B_{12}$ / folate deficiency, presence of chronic renal or liver disease; after administration of high-dose vitamin E / C; or erythropoietin treatment.

Reference: Glycated hemoglobin monitoring BMJ 2006; 333;586-8

#### References

- 1. Chamberlain JJ, Rhinehart AS, Shaefer CF, et al. Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes. Ann Intern Med. Published online 1 March 2016. doi:10.7326/M15-3016.
- 2. Mosca A, Goodall I, Hoshino T, Jeppsson JO, John WG, Little RR, Miedema K, Myers GL, Reinauer H, Sacks DB, Weykamp CW. International Federation of Clinical Chemistry and Laboratory Medicine, IFCC Scientific Division. Global standardization of glycated hemoglobin measurement: the position of the IFCC Working Group. Clin Chem Lab Med. 2007;45(8):1077-1080.

#### PDF Attached

*THYROID PANEL (T3, T4, TSH), GEL SERUM			
T3-TOTAL (TRI IODOTHYRONINE) (Method:CLIA)	1.20	0.9 - 2.2 ng/ml	ng/ml
T4-TOTAL (THYROXINE) (Method:CLIA)	9.4	5.5-16 microgram/dl	5.5-16 microgram/dl
TSH (THYROID STIMULATING HORMONE) (Method:CLIA)	2.5	0.5-4.7	μIU/mL

#### BIOLOGICAL REFERENCE INTERVAL: [ONLY FOR PREGNANT MOTHERS]

Trimester specific TSH LEVELS during pregnancy:
FIRST TRIMESTER : 0.10 2.50 µ IU/mL
SECOND TRIMESTER : 0.20 3.00 µ IU/mL
THIRD TRIMESTER : 0.30 3.00 µ IU/mL

## References :

- 1.Indian Thyroid Society guidelines for management of thyroid dysfunction during pregnancy. Clinical Practice Guidelines, New Delhi: Elsevier; 2012.
- 2.Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R, et al. Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and Postpartum. Thyroid 2011;21:1081-25.
- 3. Dave A, Maru L, Tripathi M. Importance of Universal screening for thyroid disorders in first trimester of pregnancy. Indian J Endocr Metab [serial online] 2014 [cited 2014 Sep 25]; 18: 735-8. Available from: http://www.ijem.in/text.asp?2014/18/5/735/139221.

SGOT/AST (Method:IFCC Kinetic Method)	30	< 40	U/L
POTASSIUM,BLOOD (Method:ISE DIRECT)	4.20	3.1-5.5 mEq/L	mEq/L
GLUCOSE,FASTING (Method:GOD POD)	91	(70 - 110 mg/dl)	mg/dL
URIC ACID,BLOOD (Method:URICASE)	4.70	3.4 - 7.0	mg/dl
UREA,BLOOD (Method:UREASE-GLDH)	20.8	12.8-42.8	mg/dl
CALCIUM,BLOOD (Method:ARSENAZO III)	9.90	8.6 - 10.2 mg/dl	mg/dL

\*LIPID PROFILE, GEL SERUM

**Lab No.**: DUR/13-01-2024/SR8628592 Page 3 of 11



 Lab No.
 : DUR/13-01-2024/SR8628592
 Lab Add.
 : CITY CENTER, DURGAPUR PIN-7132

 Patient Name
 : RAJESH KUMAR CHATTERJEE
 Ref Dr.
 : Dr.MEDICAL OFFICER

 Age
 : 51 Y 8 M 14 D
 Collection Date
 : 13/Jan/2024 10:15AM

 Gender
 : M
 Report Date
 : 13/Jan/2024 04:24PM



## DEPARTMENT OF BIOCHEMISTRY

Test Name	Result	Bio Ref. Interval	Unit
CHOLESTEROL-TOTAL (Method:CHOD PAP Method)	126	Desirable: < 200 mg/dL Borderline high: 200-239 High: > or =240 mg/dL	mg/dL
TRIGLYCERIDES (Method:GPO-PAP)	<u>191</u>	NORMAL < 150 BORDERLINE HIGH 150-199 HIGH 200-499 VERY HIGH > 500	mg/dL
HDL CHOLESTEROL (Method:DIRECT METHOD)	52	35.3-79.5 mg/dl	mg/dL
LDL CHOLESTEROL DIRECT (Method:Direct Method)	57	OPTIMAL: <100 mg/dL, Near optimal/ above optimal: 100-129 mg/dL, Borderline high: 130-159 mg/dL, High: 160-189 mg/dL, Very high: >=190 mg/dL	mg/dL
VLDL (Method:Calculated)	17	< 40 mg/dl	mg/dL
CHOL HDL Ratio (Method:Calculated)	<u>2.4</u>	LOW RISK 3.3-4.4 AVERAGE RISK 4.47-7.1 MODERATE RISK 7.1-11.0 HIGH RISK >11.0	
CHLORIDE,BLOOD (Method:ISE DIRECT)	98	98 - 107	mEq/L

\*\*\* End Of Report \*\*\*

**Lab No.** : DUR/13-01-2024/SR8628592

Page 4 of 11

Dr Sayak Biswas MBBS, MD Consultant Pathologist









**Lab No.** : DUR/13-01-2024/SR8628592

: RAJESH KUMAR CHATTERJEE

Age : 51 Y 8 M 14 D

Gender : M

**Patient Name** 

Lab Add. : Newtown, Kolkata-700156

**Ref Dr.** : Dr.MEDICAL OFFICER

Collection Date : 13/Jan/2024 10:42AM

Report Date : 13/Jan/2024 08:10PM

## DEPARTMENT OF BIOCHEMISTRY

Test Name Result Bio Ref. Interval Unit

URIC ACID, URINE, SPOT URINE

URIC ACID, SPOT URINE 14.00 37-92 mg/dL mg/dL

(Method:URICASE)

Suggested follow up

Correlate clinically

\*\*\* End Of Report \*\*\*

Dr. SANCHAYAN SINHA MBBS, MD, DNB (BIOCHEMISTRY) CONSULTANT BIOCHEMIST

Page 5 of 11



Unit

pg

%

fL

gm/dl

 Patient Name
 : RAJESH KUMAR CHATTERJEE
 Ref Dr.
 : Dr.MEDICAL OFFICER

 Age
 : 51 Y 8 M 14 D
 Collection Date
 : 13/Jan/2024 10:15AM

 Gender
 : M
 Report Date
 : 13/Jan/2024 04:23PM

Result

30.3

32.8

<u>14.9</u>

31.4

13.5

Test Name

MCH

**MCHC** 

(Method:Calculated)

(Method:Calculated)

(Method:Calculated)

(Method:Calculated)

(Method:Calculated)

RDW - RED CELL DISTRIBUTION WIDTH

PDW-PLATELET DISTRIBUTION WIDTH

MPV-MEAN PLATELET VOLUME



### DEPARTMENT OF HAEMATOLOGY

Bio Ref. Interval

1stHour	20	0.00 - 20.00 mm/hr	mm/hr
(Method:Westergren)	20	0.00 - 20.00 mm/m	mm/hr
(Method. Westergreit)			
CBC WITH PLATELET (THROMBOCYTE	) COUNT , EDTA W	VHOLE BLOOD	
HEMOGLOBIN (Method:PHOTOMETRIC)	13.5	13 - 17	g/dL
WBC (Method:DC detection method)	4.1	4 - 10	*10^3/µL
RBC (Method:DC detection method)	<u>4.44</u>	4.5 - 5.5	*10^6/µL
PLATELET (THROMBOCYTE) COUNT (Method:DC detection method/Microscopy)  DIFFERENTIAL COUNT	<u>130</u>	150 - 450*10^3	*10^3/µL
NEUTROPHILS (Method:Flowcytometry/Microscopy)	66	40 - 80 %	%
LYMPHOCYTES (Method:Flowcytometry/Microscopy)	22	20 - 40 %	%
MONOCYTES (Method:Flowcytometry/Microscopy)	05	2 - 10 %	%
EOSINOPHILS (Method:Flowcytometry/Microscopy)	<u>07</u>	1 - 6 %	%
BASOPHILS (Method:Flowcytometry/Microscopy)  CBC SUBGROUP	00	0-0.9%	%
HEMATOCRIT / PCV (Method:Calculated)	41.1	40 - 50 %	%
MCV (Method:Calculated)	92.4	83 - 101 fl	fl

\*\*\* End Of Report \*\*\*

27 - 32 pg

11.6-14%

8.3 - 25 fL

7.5 - 11.5 fl

31.5-34.5 gm/dl

Dr Sayak Biswas MBBS, MD Consultant Pathologist

**Lab No.** : DUR/13-01-2024/SR8628592 Page 6 of 11









Patient Name: RAJESH KUMAR CHATTERJEERef Dr.: Dr.MEDICAL OFFICER

 Age
 : 51 Y 8 M 14 D
 Collection Date
 : 13/Jan/2024 10:15AM

**Gender** : M Report Date : 13/Jan/2024 07:01PM



### DEPARTMENT OF HAEMATOLOGY

Test Name Result Bio Ref. Interval Unit

BLOOD GROUP ABO+RH [GEL METHOD], EDTA WHOLE BLOOD

ABO E

(Method:Gel Card)

RH POSITIVE

(Method:Gel Card)

#### **TECHNOLOGY USED: GEL METHOD**

#### ADVANTAGES:

- · Gel card allows simultaneous forward and reverse grouping.
- · Card is scanned and record is preserved for future reference.
- · Allows identification of Bombay blood group.
- Daily quality controls are run allowing accurate monitoring.

Historical records check not performed.

\*\*\* End Of Report \*\*\*

Kaushin Dey

MD (PATHOLOGY)
CONSULTANT PATHOLOGIST



Lab No. : DUR/13-01-2024/SR8628592 Lab Add. : CITY CENTER, DURGAPUR PIN-7132

 Patient Name
 : RAJESH KUMAR CHATTERJEE
 Ref Dr.
 : Dr.MEDICAL OFFICER

 Age
 : 51 Y 8 M 14 D
 Collection Date
 : 13/Jan/2024 10:43AM

 Gender
 : M
 Report Date
 : 13/Jan/2024 04:24PM



#### DEPARTMENT OF CLINICAL PATHOLOGY

Test Name	Result	Bio Ref. Interval	Unit
*URINE ROUTINE ALL, ALL, URINE			
PHYSICAL EXAMINATION			
COLOUR APPEARANCE	PALE YELLOW CLEAR		
CHEMICAL EXAMINATION	OLL/III		
pH (Method:Dipstick (triple indicator method))	5.5	4.6 - 8.0	
SPECIFIC GRAVITY (Method:Dipstick (ion concentration method))	1.015	1.005 - 1.030	
PROTEIN (Method:Dipstick (protein error of pH indicators)/Manual)	NOT DETECTED	NOT DETECTED	
GLUCOSE (Method:Dipstick(glucose-oxidase-peroxidase method)/Manual)	NOT DETECTED	NOT DETECTED	
KETONES (ACETOACETIC ACID, ACETONE) (Method:Dipstick (Legals test)/Manual)	NOT DETECTED	NOT DETECTED	
BLOOD (Method:Dipstick (pseudoperoxidase reaction))	NOT DETECTED	NOT DETECTED	
BILIRUBIN (Method:Dipstick (azo-diazo reaction)/Manual)	NEGATIVE	NEGATIVE	
UROBILINOGEN (Method:Dipstick (diazonium ion reaction)/Manual)	NEGATIVE	NEGATIVE	
NITRITE (Method:Dipstick (Griess test))	NEGATIVE	NEGATIVE	
LEUCOCYTE ESTERASE (Method:Dipstick (ester hydrolysis reaction))  MICROSCOPIC EXAMINATION	NEGATIVE	NEGATIVE	
LEUKOCYTES (PUS CELLS) (Method:Microscopy)	0-1	0-5	/hpf
EPITHELIAL CELLS (Method:Microscopy)	0-1	0-5	/hpf
RED BLOOD CELLS (Method:Microscopy)	NOT DETECTED	0-2	/hpf
CAST (Method:Microscopy)	NOT DETECTED	NOT DETECTED	
CRYSTALS (Method:Microscopy)	NOT DETECTED	NOT DETECTED	
BACTERIA	NOT DETECTED	NOT DETECTED	

## Note:

YEAST

(Method:Microscopy)

(Method:Microscopy)

- $1. \ All \ urine \ samples \ are \ checked \ for \ adequacy \ and \ suitability \ before \ examination.$
- 2. Analysis by urine analyzer of dipstick is based on reflectance photometry principle. Abnormal results of chemical examinations are confirmed by manual methods.

NOT DETECTED

3. The first voided morning clean-catch midstream urine sample is the specimen of choice for chemical and microscopic analysis.

NOT DETECTED

- 4. Negative nitrite test does not exclude urinary tract infections.
- 5. Trace proteinuria can be seen in many physiological conditions like exercise, pregnancy, prolonged recumbency etc.
- 6. False positive results for glucose, protein, nitrite, urobilinogen, bilirubin can occur due to use of certain drugs, therapeutic dyes, ascorbic acid, cleaning agents used in urine collection container.
- 7. Discrepancy between results of leukocyte esterase and blood obtained by chemical methods with corresponding pus cell and red blood cell count by microscopy can occur due to cell lysis.
- 8. Contamination from perineum and vaginal discharge should be avoided during collection, which may falsely elevate epithelial cell count and show presence of bacteria

  Lab No. : DUR/13-01-2024/SR8628592 Page 8 of 11



 Lab No.
 : DUR/13-01-2024/SR8628592
 Lab Add.
 : CITY CENTER, DURGAPUR PIN-7132

 Patient Name
 : RAJESH KUMAR CHATTERJEE
 Ref Dr.
 : Dr.MEDICAL OFFICER

 Age
 : 51 Y 8 M 14 D
 Collection Date
 : 13/Jan/2024 10:43AM

 Gender
 : M
 Report Date
 : 13/Jan/2024 04:24PM



### DEPARTMENT OF CLINICAL PATHOLOGY

Test Name Result Bio Ref. Interval Unit

and/or yeast in the urine.

\*\*\* End Of Report \*\*\*

Dr Sayak Biswas MBBS, MD Consultant Pathologist

**Lab No.** : DUR/13-01-2024/SR8628592 Page 9 of 11



 Patient Name
 : RAJESH KUMAR CHATTERJEE
 Ref Dr.
 : Dr.MEDICAL OFFICER

Age : 51 Y 8 M 14 D Collection Date :

 Gender
 : M
 Report Date
 : 13/Jan/2024 05:27PM



# DEPARTMENT OF CARDIOLOGY REPORT OF E.C.G.

IMPRESSION	:	• Sinus Tachycardia.
T WAVE	28	Degree
QRS WAVE	64	Degree
P WAVE	43	Degree
AXIS		
QTC INTERVAL	410	Ms
QT INTERVAL	316	Ms
QRS DURATION	82	Ms
PR INTERVAL	142	Ms
HEART RATE	101	Врт
DATA		

\*\*\*Please correlate clinically\*\*\*

\*\*\* End Of Report \*\*\*

Dr. Abhijit Ghosh

M.D.DipCard(PGDCC)Apollohospital,chennai

CCEBDM.CCMH

Consultant Clinical Cardiologist



 Patient Name
 : RAJESH KUMAR CHATTERJEE
 Ref Dr.
 : Dr.MEDICAL OFFICER

Age : 51 Y 8 M 14 D Collection Date :

**Gender** : M Report Date : 13/Jan/2024 01:07PM



### DEPARTMENT OF ULTRASONOGRAPHY

#### REPORT ON EXAMINATION OF WHOLE ABDOMEN

**LIVER:** Normal in size (13.65 cm), shape with *moderate increased echogenicity suggesting fat infiltration grade II.* No definite focal lesion is seen. Intrahepatic biliary radicles are not dilated. The portal vein branches and hepatic veins are normal.

**GALL BLADDER**: Well distended lumen shows no intra-luminal calculus or mass. Wall thickness is normal. No pericholecystic collection or mass formation is noted.

**PORTA HEPATIS:** The portal vein is normal in caliber (0.90 cm) with clear lumen. The common bile duct is normal in caliber. Visualized lumen is clear. Common bile duct measures approx (0.30 cm) in diameter.

**PANCREAS**: It is normal in size, shape and echopattern. Main pancreatic duct is not dilated. No focal lesion of altered echogenicity is seen. The peripancreatic region shows no abnormal fluid collection.

**SPLEEN**: It is normal in size (10.82 cm), shape and shows homogeneous echopattern. No focal lesion is seen. No abnormal venous dilatation is seen in the splenic hilum.

**KIDNEYS**: Both kidneys are normal in size, shape and position. Cortical echogenicity and thickness are normal with normal cortico-medullary differentiation in both kidneys. No calculus, hydronephrosis or mass is noted. The perinephric region shows no abnormal fluid collection. Right Kidney measures: 9.54 cm and Left Kidney measures: 9.46 cm.

**URETER**: Both ureters are not dilated. No calculus is noted in either side.

**PERITONEUM & RETROPERITONEUM:** The aorta and IVC are normal. Lymph nodes are not enlarged. No free fluid is seen in peritoneal cavity.

**URINARY BLADDER:** It is adequately distended providing optimum scanning window. The lumen is clear and wall thickness is normal.

**PROSTATE:** It is normal in size, shape and echopattern. No focal lesion is seen. Capsule is smooth. Prostate measures: 3.01 cm x 2.87 cm x 2.32 cm, weight 10 gms.

## **IMPRESSION:**

• Fatty liver grade II.

\*\*\* Please correlate clinically.

#### Kindly note

Ultrasound is not the modality of choice to rule out subtle bowel lesion

Please Intimate us for any typing mistakes and send the report for correction within 7 days.

The science of Radiological diagnosis is based on the interpretation of various shadows produced by both the normal and abnormal tissues and are not always conclusive. Further biochemical and radiological investigation & clinical correlation is required to enable the clinician to reach the final diagnosis.

The report and films are not valid for medico-legal purpose.

Patient Identity not verified.

Dr Nidhi Sehgal DNB (Radio-diagnosis) Senior Consultant Radiologist